IRIS
SACCA', FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.644
EU - Europa 1.527
AS - Asia 851
AF - Africa 44
SA - Sud America 6
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 1
Totale 5.076
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.609
IT - Italia 723
SG - Singapore 453
CN - Cina 274
NL - Olanda 241
DE - Germania 147
UA - Ucraina 132
IE - Irlanda 92
FI - Finlandia 71
IN - India 59
GB - Regno Unito 52
CI - Costa d'Avorio 43
VN - Vietnam 38
CA - Canada 32
FR - Francia 19
SE - Svezia 14
IR - Iran 8
JP - Giappone 7
CZ - Repubblica Ceca 6
HK - Hong Kong 6
PT - Portogallo 6
BG - Bulgaria 5
ES - Italia 5
BR - Brasile 4
CH - Svizzera 4
BZ - Belize 2
EU - Europa 2
GR - Grecia 2
PH - Filippine 2
RO - Romania 2
AP - ???statistics.table.value.countryCode.AP??? 1
AU - Australia 1
BE - Belgio 1
CL - Cile 1
CO - Colombia 1
HR - Croazia 1
MK - Macedonia 1
MT - Malta 1
MX - Messico 1
PK - Pakistan 1
PL - Polonia 1
QA - Qatar 1
RS - Serbia 1
TH - Thailandia 1
TR - Turchia 1
ZA - Sudafrica 1
Totale 5.076
Salva come PNG Salva come JPEG
Città #
Chandler 603
Singapore 363
Amsterdam 231
Ashburn 200
Millbury 135
Santa Clara 131
Naples 130
Beijing 91
Nanjing 81
Princeton 80
Napoli 73
Des Moines 72
Boston 52
Lawrence 46
Wilmington 42
Jacksonville 40
Cava De' Tirreni 38
Dong Ket 38
Milan 38
Nola 33
Norwalk 32
Seattle 31
Rome 25
Ottawa 23
Dearborn 21
Pune 21
Nanchang 17
Dallas 16
Munich 16
Redwood City 14
Jiaxing 12
Leawood 12
Los Angeles 12
Torre Annunziata 12
Dublin 11
Hebei 11
San Jose 11
San Mateo 11
Tianjin 11
Woodbridge 11
Latina 10
Washington 10
Houston 9
Changsha 8
Boardman 7
Kronberg 7
Le Cannet 7
Sant'arpino 7
Shenyang 7
Toronto 7
Acerra 6
Helsinki 6
Hong Kong 6
Lappeenranta 6
London 6
Augusta 5
Caserta 5
Davis 5
Fairfield 5
Formia 5
New York 5
Padova 5
Portici 5
Sofia 5
Buffalo 4
Fremont 4
Indiana 4
Kunming 4
Madrid 4
Poli 4
Stockholm 4
Telese 4
Bologna 3
Brno 3
Brusciano 3
Castellammare Di Stabia 3
Changchun 3
Duque de Caxias 3
Guangzhou 3
Lanzhou 3
Lviv 3
Marano di Napoli 3
Messina 3
Mumbai 3
Nuremberg 3
Poggiomarino 3
Saint Louis 3
Salerno 3
San Francisco 3
Tehran 3
Verona 3
Andover 2
Ann Arbor 2
Ardabil 2
Arzano 2
Aversa 2
Belize City 2
Chengdu 2
Darmstadt 2
Eboli 2
Totale 3.108
Salva come PNG Salva come JPEG
Nome #
Ofatumumab versus Teriflunomide in Multiple Sclerosis 88
Ataxia-myoclonus syndrome due to a novel homozygous ATP13A2 mutation 75
A genome-wide association meta-analysis identifies a novel locus at 17q11.2 associated with sporadic amyotrophic lateral sclerosis. 72
Ataxia with oculomotor apraxia type 1 in southern italy: late onset and variable phenotype. 66
Epoetin alfa increases frataxin production in Friedreich's ataxia without affecting hematocrit. 66
Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study 65
Modifications of resting state networks in spinocerebellar ataxia type 2 64
Multiple hormone deficiency syndrome in heart failure with preserved ejection fraction 62
Dural sinus collapsibility, idiopathic intracranial hypertension, and the pathogenesis of chronic migraine 62
Cost-Effectiveness Analysis of Cannabinoid Oromucosal Spray Use for the Management of Spasticity in Subjects with Multiple Sclerosis 61
Dimethyl Fumarate Mediates Nrf2-dependent Mitochondrial Biogenesis in Mice and Humans 60
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study 60
Alterations of functional connectivity of the motor cortex in Fabry disease: An RS-fMRI study 59
Pathological laughter as onset symptom in atypical parkinsonisms 58
Vascular smooth muscle cell dysfunction in patients with migraine. 57
The use of medical-grade cannabis in patients non-responders to Nabiximols 57
Recombinant human erythropoietin increasesfrataxin protein expression without increasing mRNA expression 55
A randomized controlled pilot trial of lithium in spinocerebellar ataxia type 2. 55
Multiple hormone deficiencies in chronic heart failure 55
Lamivudine and fingolimod co-administration in two patients with multiple sclerosis and occult hepatitis B virus infection 54
A 8-year retrospective cohort study comparing Interferon-beta formulations for relapsing-remitting multiple sclerosis 53
Emotion Recognition and Psychological Comorbidity in Friedreich’s Ataxia 53
Cognitive and functional connectivity alterations in Friedreich's ataxia 53
Dimethyl fumarate dosing in humans increases frataxin expression: A potential therapy for Friedreich’s Ataxia 53
Application of the p9NORM correction method to timed neuropsychological tests in Parkinson's disease and multiple system atrophy. 53
Cerebellum and cognition in Friedreich ataxia: a voxel-based morphometry and volumetric MRI study 53
Ataxia with oculomotor apraxia type 2: a clinical, pathologic, and genetic study 52
Default mode network modifications in Fabry disease: A resting-state fMRI study with structural correlations 51
Long-term therapy with miglustat and cognitive decline in the adult form of Niemann-Pick disease type C: a case report 51
Very late onset in ataxia oculomotor apraxia type I. 50
Detectable interleukin-9 plasma levels are associated with impaired cardiopulmonary functional capacity and all-cause mortality in patients with chronic heart failure 50
Clinical predictors of Dimethyl Fumarate response in multiple sclerosis: a real life multicentre study 50
Ataxia with oculomotor apraxia type 1 in Southern Italy: late onset and variable phenotype 49
Frontal defect contribution to decreasing of body mass index in Parkinson's disease patients 49
Post-mortem diagnosis of invasive pulmonary aspergillosis after alemtuzumab treatment for multiple sclerosis 49
Cognitive impairment at diagnosis predicts 10-year multiple sclerosis progression 48
The EDSS integration with the Brief International Cognitive Assessment for Multiple Sclerosis and orientation tests 47
CD4/CD8 ratio during natalizumab treatment in multiple sclerosis patients 47
Novel mutation of SACS gene in a Spanish family with autosomal recessive spastic ataxia 46
A randomized clinical trial of lithium in multiple system atrophy. 46
Long-term effect of epoetin alfa on clinical and biochemical markers in friedreich ataxia 46
Immunometabolic profiling of patients with multiple sclerosis identifies new biomarkers to predict disease activity during treatment with interferon beta-1a 46
Striatonigral involvement in Fabry Disease: A quantitative and volumetric Magnetic Resonance Imaging study 46
Longitudinal study of a cohort of MSA-C patients in South Italy: survival and clinical features 46
Normalization of timed neuropsychological tests with the PATA rate and nine-hole pegboard tests 45
Predictors of survival in spinocerebellar ataxia type 2 population from Southern Italy. 45
A 8-year retrospective cohort study comparing Interferon-β formulations for relapsing-remitting multiple sclerosis 45
Myocardial (123)I-metaiodobenzylguanidine scintigraphy in patients with homozygous and heterozygous parkin mutations 44
Peripheral markers of autophagy in polyglutamine diseases 44
Adult normative values for the PATA Rate Test 44
Benign hereditary chorea: clinical and neuroimaging features in an Italian family. 43
A randomized controlled clinical trial of growth hormone in amyotrophic lateral sclerosis: clinical, neuroimaging, and hormonal results. 43
Be aware of Wolfram syndrome when examining ataxic patients 43
Stability of erythropoietin repackaging in polypropylene syringes for clinical use 43
The flavor test is a sensitive tool in identifying the flavor sensorineural dysfunction in Parkinson's disease 43
Variable phenotype in a P102L Gerstmann-Straussler-Scheinker Italian family 42
A randomized trial of varenicline (Chantix) for the treatment of spinocerebellar ataxia type 3. 42
Screening for dopa-responsive dystonia in patients with scans without evidence of dopaminergic deficiency (SWEDD). 42
Assessment of neuroactive steroids in cerebrospinal fluid comparing acute relapse and stable disease in relapsing-remitting multiple sclerosis 42
Functional MRI signal fluctuations highlight altered resting brain activity in Huntington’s disease 42
Chronic Pachymeningitis: a case of neurosyphilis with spastic paraparesis. 41
A longitudinal real-life comparison study of natalizumab and fingolimod 41
Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study 41
A snapshot on patient-reported outcome measures of people with multiple sclerosis on first-line therapies in a real world setting 41
‘Minimal symptom expression’ in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab 41
Autosomal recessive progressive myoclonus epilepsy with ataxia and mental retardation. 40
Mobitz type I and II atrioventricular blocks during fingolimod therapy 40
Aprataxin 39
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study 39
Cognitive trajectories in multiple sclerosis: a long-term follow-up study 39
The combined use of conventional MRI and MR spectroscopic imaging increases the diagnostic accuracy in amyotrophic lateral sclerosis. 38
Autosomal recessive progressive myoclonus epilepsy with ataxia and mental retardation. 36
Assessing association of comorbidities with treatment choice and persistence in MS: A real-life multicenter study 36
Friedreich ataxia: 150 years of bench and bedside studies 36
Bacterial and CMV pneumonia in a patient treated with alemtuzumab for multiple sclerosis 36
The “crab sign”: an imaging feature of spinocerebellar ataxia type 48 36
Effects of THC/CBD oromucosal spray on spasticity-related symptoms in people with multiple sclerosis: results from a retrospective multicenter study 36
Insulin Sensitivity and Early-Phase Insulin Secretion in Normoglycemic Huntington's Disease Patients 35
A combined nucleic acid and protein analysis in Friedreich ataxia: implications for diagnosis, pathogenesis and clinical trial design. 34
Fingolimod first dose safety in clinical practice. 34
Outcomes after fingolimod to alemtuzumab treatment shift in relapsing–remitting MS patients: a multicentre cohort study 34
Consistent improvement with eculizumab across muscle groups in myasthenia gravis 34
Eculizumab improves fatigue in refractory generalized myasthenia gravis 33
Variable phenotype in a P102L Gerstmann-Sträussler-Scheinker Italian family. 32
Long-term safety and efficacy of eculizumab in generalized myasthenia gravis 32
Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis 31
Reduced intracranial volume in Fabry Disease: Evidence of abnormal neurodevelopment? 31
Cladribine vs other drugs in MS: Merging randomized trial with real-life data 31
SCA Functional Index: a useful compound performance measure for spinocerebellar ataxia. 30
Metabolic Ataxias in Adults. 29
Cardiovascular profile improvement during Natalizumab treatment 29
The Multiple Faces of Spinocerebellar Ataxia type 2 29
Jaw-Opening Oromandibular Dystonia Associated With Spinocerebellar Ataxia Type 2 29
Google Trends: New evidence for seasonality of multiple sclerosis 28
Fingolimod reduces the clinical expression of active demyelinating lesions in MS 28
Degenerative and acquired sporadic adult onset ataxia 28
Variability of multiple sclerosis spasticity symptoms in response to THC:CBD oromucosal spray: Tracking cases through clinical scales and video recordings 28
Olfactory function and cognition in relapsing–remitting and secondary-progressive multiple sclerosis 27
The complex phenotype of spinocerebellar ataxia type 48 in eight unrelated Italian families 27
Overt Hypogonadism May Not Be a Sentinel Sign of RING Finger Protein 216: Two Novel Mutations Associated with Ataxia, Chorea, and Fertility 27
Totale 4.486
Salva come PNG Salva come JPEG
Categoria #
all - tutte 24.302
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.302
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020291 0 0 0 0 21 34 34 14 12 101 63 12
2020/2021469 38 19 23 45 41 97 30 25 39 17 47 48
2021/2022830 16 10 10 4 12 54 18 44 94 72 191 305
2022/20231.391 151 124 47 108 153 167 12 108 214 233 53 21
2023/2024933 30 125 108 51 44 100 5 150 12 22 198 88
2024/2025692 210 221 37 82 142 0 0 0 0 0 0 0
Totale 5.425